Koyfin Home > Directory > Health Care > Apellis Pharmaceuticals Inc > EBITDA

Apellis Pharmaceuticals Inc EBITDA Chart (APLS)

Apellis Pharmaceuticals Inc annual/quarterly EBITDA from 2017 to 2018. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Apellis Pharmaceuticals Inc EBITDA for the quarter ending December 12, 2018 was $-37m a 42.92% decrease of -16m year over year
  • Apellis Pharmaceuticals Inc EBITDA for the last 12 months ending December 12, 2018 was $-128m a 87.47% decrease of -112m year over year
  • Apellis Pharmaceuticals Inc Annual EBITDA for 2018 was $-128m a 60.32% decrease of -77m from 2017
  • Apellis Pharmaceuticals Inc Annual EBITDA for 2017 was $-51m a 60.44% decrease of -31m from 2016
  • Apellis Pharmaceuticals Inc Annual EBITDA for 2015 was $-20m
Other Income Statement Metrics:
  • Apellis Pharmaceuticals Inc Net Income for the quarter ending December 12, 2018 was $-36m a 40.38% decrease of -15m year over year
View Chart On Koyfin

Quarterly APLS EBITDA Data

12/2018$-37m
09/2018$-36m
06/2018$-33m
03/2018$-21m
12/2017$-18m

Annual APLS EBITDA Data

2018$-128m
2017$-51m
2015$-20m